Belgian radiopharmaceutical firm Ion Beam Applications (IBA) of Louvain-la-Neuve has moved to finalize its purchase of CIS bio International, the company reported.
IBA will exercise its option to buy 80.1% of the indirect interest in CIS bio held by the Institut National des Radioéléments (IRE) of Fleurus, Belgium. The purchase price will be 20 million euros ($31 million); IBA will pay 50% in cash and 50% in stock.
The cash payment will be used to start projects useful to the development of IRE, CIS bio, and IBA, the company said.
Related Reading
IBA opens U.K. production center, March 14, 2008
IBA posts mixed results for 2007, March 7, 2008
IBA inks French particle-beam therapy deal, February 7, 2008
IBA finalizes proton therapy deal, December 21, 2007
FDA OKs Compass dosimetry device, December 18, 2007
Copyright © 2008 AuntMinnie.com
